Total Payments
$722,624
2024 Payments
$55,395
Companies
19
Transactions
1,028
Medicare Patients
289
Medicare Billing
$31,752
Payment Breakdown by Category
Other$508,869 (70.4%)
Travel$86,456 (12.0%)
Consulting$60,251 (8.3%)
Research$49,535 (6.9%)
Food & Beverage$17,401 (2.4%)
Education$112.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $293,198 | 110 | 40.6% |
| Honoraria | $215,671 | 99 | 29.8% |
| Travel and Lodging | $86,456 | 359 | 12.0% |
| Consulting Fee | $60,251 | 27 | 8.3% |
| Unspecified | $49,535 | 31 | 6.9% |
| Food and Beverage | $17,401 | 388 | 2.4% |
| Education | $112.32 | 14 | 0.0% |
Payments by Type
General
$673,089
997 transactions
Research
$49,535
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $283,563 | 393 | $0 (2019) |
| Pharming Healthcare, Inc. | $218,619 | 241 | $0 (2024) |
| CSL Behring | $92,116 | 143 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $80,808 | 89 | $0 (2024) |
| BioCryst US Sales Co., LLC | $39,589 | 79 | $0 (2024) |
| BioCryst Pharmaceuticals, Inc. | $5,208 | 10 | $0 (2020) |
| Cycle Pharmaceuticals Inc | $650.55 | 2 | $0 (2024) |
| Circassia Pharmaceuticals Inc | $535.00 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $488.21 | 11 | $0 (2024) |
| GlaxoSmithKline, LLC. | $374.01 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,395 | 79 | Pharming Healthcare, Inc. ($26,060) |
| 2023 | $41,045 | 67 | Pharming Healthcare, Inc. ($21,135) |
| 2022 | $70,588 | 93 | Pharming Healthcare, Inc. ($35,765) |
| 2021 | $63,966 | 113 | Pharming Healthcare, Inc. ($18,332) |
| 2020 | $79,970 | 99 | Pharming Healthcare, Inc. ($28,354) |
| 2019 | $86,256 | 140 | Pharming Healthcare, Inc. ($56,076) |
| 2018 | $155,445 | 243 | Shire North American Group Inc ($114,174) |
| 2017 | $169,959 | 194 | Shire North American Group Inc ($156,819) |
All Payment Transactions
1,028 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: BIOLOGIC | ||||||
| 12/12/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: BIOLOGIC | ||||||
| 12/10/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Immunology | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: BIOLOGIC | ||||||
| 12/02/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Immunology | ||||||
| 11/15/2024 | CSL Behring | Haegarda (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/06/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $122.74 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Cycle Pharmaceuticals Inc | Sajazir (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Immunology | ||||||
| 10/29/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 10/24/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| 10/22/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: BIOLOGIC | ||||||
| 10/03/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,140.00 | General |
| Category: Immunology | ||||||
| 10/01/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,140.00 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $642.25 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $211.29 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $87.20 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $84.44 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $46.31 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $32.50 | General |
| Category: BIOLOGIC | ||||||
| 09/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $18.42 | General |
| Category: BIOLOGIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,TWO-PERIOD, THREE-SEQUENCE, PARTIAL CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF 2000 U OF C1 ESTERASE INHIBITOR HUMAN LIQUID FOR INJECTION FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $39,824 | 14 |
| AN OBSERVATIONAL, NON-INTERVENTIONAL, STUDY OF PATIENTS WITH HEREDITARY ANGIOEDEMA IN THE UNITED STATES AND CANADA (EMPOWER STUDY) | Takeda Pharmaceuticals U.S.A., Inc. | $4,907 | 15 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LANADELUMAB FOR PREVENTION AGAINST ACUTE ATTACKS OF NON-HISTAMINERGIC ANGIOEDEMA WITH NORMAL C1-INHIBITOR (C1-INH) AND ACQUIRED ANGIOEDEMA (AAE) DUE TO C1-INH DEFICIENCY | Takeda Pharmaceuticals U.S.A., Inc. | $4,804 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 79 | 88 | $40,733 | $9,040 |
| 2022 | 3 | 51 | 58 | $23,741 | $5,829 |
| 2021 | 4 | 94 | 108 | $40,438 | $10,497 |
| 2020 | 3 | 65 | 73 | $27,686 | $6,386 |
Total Patients
289
Total Services
327
Medicare Billing
$31,752
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 34 | $14,484 | $3,043 | 21.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $10,431 | $2,620 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $8,688 | $1,779 | 20.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 23 | $7,130 | $1,598 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 27 | $11,502 | $2,852 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $6,039 | $1,629 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 20 | $6,200 | $1,349 | 21.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 24 | 24 | $13,040 | $3,519 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 46 | $12,832 | $3,145 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 25 | $9,858 | $2,803 | 28.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $4,708 | $1,030 | 21.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 26 | 26 | $14,205 | $3,278 | 23.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 26 | 32 | $7,986 | $1,983 | 24.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 15 | $5,495 | $1,125 | 20.5% |
About Dr. Jay Kashkin, MD
Dr. Jay Kashkin, MD is a Allergy healthcare provider based in Fair Lawn, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1235128497.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Kashkin, MD has received a total of $722,624 in payments from pharmaceutical and medical device companies, with $55,395 received in 2024. These payments were reported across 1,028 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($293,198).
As a Medicare-enrolled provider, Kashkin has provided services to 289 Medicare beneficiaries, totaling 327 services with total Medicare billing of $31,752. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Fair Lawn, NJ
- Active Since 10/19/2005
- Last Updated 07/08/2007
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1235128497
Products in Payments
- CINRYZE (Drug) $297,042
- RUCONEST (Biological) $218,619
- Haegarda (Biological) $85,585
- TAKHZYRO (Biological) $29,685
- ORLADEYO (Drug) $28,096
- Orladeyo (Drug) $11,493
- DUPIXENT (Biological) $650.28
- NITYR (Drug) $630.00
- NIOX VERO (Device) $535.00
- NUCALA (Biological) $243.53
- DUPIXENT (Drug) $113.33
- AUVI-Q (Drug) $75.94
- TRELEGY ELLIPTA (Drug) $72.88
- BREO (Drug) $57.60
- ALVESCO (Drug) $54.00
- Berinert 500U (Biological) $37.79
- CUVITRU (Biological) $33.00
- XOLAIR (Biological) $27.94
- Hizentra (Biological) $24.70
- XOLAIR (Drug) $24.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.